El consorcio formado por aptaTargets, el Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL), el Instituto de Investigaci\u00f3n Germans Trias i Pujol (IGTP), la Universidad de Valladolid y el Instituto de Investigaci\u00f3n Vall d’Hebron (VHIR) ha recibido 4 millones de euros de financiaci\u00f3n del Ministerio de Ciencia e Innovaci\u00f3n de Espa\u00f1a a trav\u00e9s de la Agencia Estatal de Investigaci\u00f3n (AEI).<\/p>\n
<\/p>\n
La subvenci\u00f3n apoyar\u00e1 el proyecto NexTOLL, cuyo objetivo es lanzar un ensayo cl\u00ednico multic\u00e9ntrico de fase 2b para confirmar el efecto neuroprotector de ApTOLL en pacientes con accidente cerebrovascular isqu\u00e9mico agudo (AIS). El ensayo cl\u00ednico est\u00e1 previsto que comience en 2024 y Pere Cardona, investigador principal del grupo de investigaci\u00f3n de Enfermedades Neurol\u00f3gicas y Neurogen\u00e9tica<\/a> del IDIBELL y director del Programa Neurovascular y de la Unidad de Ictus<\/a> del Hospital Universitario de Bellvitge, estar\u00e1 entre los neur\u00f3logos que lo llevar\u00e1n a cabo.<\/p>\n <\/p>\n Estos fondos surgen de una convocatoria altamente competitiva del Programa Estatal para el Fomento de la Investigaci\u00f3n Cient\u00edfica y T\u00e9cnica y su Transferencia 2022 (anteriormente conocido como Retos Colaboraci\u00f3n) que prev\u00e9 financiaci\u00f3n para proyectos de colaboraci\u00f3n p\u00fablico-privada para catalizar la innovaci\u00f3n y el liderazgo empresarial en peque\u00f1as empresas y medianas empresas (PYMES).<\/p>\n <\/p>\n Los resultados de la investigaci\u00f3n realizada con ApTOLL hasta la fecha son muy alentadores. Se trata del primer f\u00e1rmaco neuroprotector que obtiene resultados positivos en ensayos cl\u00ednicos<\/a> con pacientes, los cuales se presentaron en la International Stroke Conference 2023 y se publicaron en la prestigiosa revista cient\u00edfica JAMA Neurology<\/a>.<\/p>\n <\/p>\n La financiaci\u00f3n recibida de la AEI es clave para llevar ApTOLL al mercado, que podr\u00eda proporcionar una opci\u00f3n terap\u00e9utica importante para los pacientes con accidente cerebrovascular que tienen una necesidad m\u00e9dica importante no cubierta.<\/p>\n <\/p>\n Un ensayo cl\u00ednico de fase IIb para evaluar el efecto neuroprotector de ApTOLL en pacientes con accidente cerebrovascular. NextTOLL CPP2022-009778.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" \u00c9xito colaborativo en el avance de la neuroprotecci\u00f3n contra accidentes cerebrovasculares<\/p>\n","protected":false},"author":8,"featured_media":23761,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[320,300,277],"tags":[],"class_list":["post-23760","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-area-neurociencias","category-enfermedades-neurologicas-y-neurogenetica","category-programa-de-neurociencias"],"publishpress_future_action":{"enabled":false,"date":"2024-10-25 02:50:57","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/23760"}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/comments?post=23760"}],"version-history":[{"count":2,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/23760\/revisions"}],"predecessor-version":[{"id":23765,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/23760\/revisions\/23765"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media\/23761"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=23760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/categories?post=23760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/tags?post=23760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}